The impact of GLP-1 RAs on lipid synthesis and oxidation in the liver, resulting in decreased inflammation and fibrosis, has led to studies evaluating their potential for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), and inflammatory bowel disease (IBD), and the prevention of hepatobiliary and other gastrointestinal (GI) cancers [1,5]. Here, GCG is linked to metabolic dysfunction-associated steatohepatitis.